Care | Page 267 of 309 | SpiritIndia.com

Dental Health :: Oragenics reports positive clinical results with its oral probiotic mouthrinse

Oragenics, Inc. (Amex: ONI) announced today that the first of two sets of subjects has completed a clinical trial utilizing its proprietary oral probiotic product, Probiora3(TM). The trial was designed to determine safety and the effectiveness of the mouthrinse against baseline levels of disease-causing bacteria in the mouth. Daily mouth rinsing with Probiora3(TM) resulted in substantial reductions in the numbers of the bacterium, S. mutans, which attacks teeth, as well as two target periodontal strains, Porphyromonas gingivalis and Campylobacter rectus, associated with gum disease and bad breath. The product was well tolerated by the subjects and no safety issues were identified with the twice daily use of the product over a two-month period.

Cancer :: Methoxyamine – new cancer therapy reverses resistance to chemotherapy

Case Western Reserve University’s Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a “first in class” drug that targets a specific DNA repair pathway.

Psoriasis :: Psoriasis associated with increased risk for heart attack

Adults with psoriasis, especially younger patients with severe psoriasis, appear to be at increased risk for a heart attack, according to a study in the October 11 issue of JAMA.

ADHD :: Preschoolers with ADHD Improve with Low Doses of Medication

The first long-term, large-scale study designed to determine the safety and effectiveness of treating preschoolers who have attention deficit/hyperactivity disorder (ADHD) with methylphenidate (Ritalin) has found that overall, low doses of this medication are effective and safe. However, the study found that children this age are more sensitive than older children to the medication?s side effects and therefore should be closely monitored. The 70-week, six-site study was funded by the National Institutes of Health?s National Institute of Mental Health (NIMH) and was described in several articles in the November 2006 issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

Alzheimer’s Disease :: Antipsychotic Medications Used to Treat Alzheimer’s Patients Found Lacking

Commonly prescribed antipsychotic medications used to treat Alzheimer?s patients with delusions, aggression, hallucinations, and other similar symptoms can benefit some patients, but they appear to be no more effective than a placebo when adverse side effects are considered, according to the first phase of a large-scale clinical trial funded by the National Institutes of Health?s National Institute of Mental Health (NIMH). The trial, known as the Clinical Antipsychotic Trial of Intervention Effectiveness study for Alzheimer?s disease (CATIE-AD), was published in the October 12, 2006, issue of the New England Journal of Medicine.

Diabetes :: Plan Will Guide NIH Research in Type 1 Diabetes

The National Institutes of Health (NIH) has released a long range plan that will help to guide research in type 1 diabetes for the next decade. Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan identifies goals and objectives to exploit recent scientific advances in combating this autoimmune form of diabetes.

Macular Degeneration :: Evaluating Effect of Antioxidants and Fish Oil on Progression of Age-Related Macular Degeneration (AMD)

The National Institutes of Health (NIH) announces a nationwide study to see if a modified combination of vitamins, minerals, and fish oil can further slow the progression of vision loss from AMD, the leading cause of vision loss in the United States for people over age 60. This new study, called the Age-Related Eye Disease Study 2 (AREDS2), will build upon results from the earlier Age-Related Eye Disease Study (AREDS). The original study results were released five years ago today. The study found that high-dose antioxidant vitamins and minerals (vitamins C and E, beta-carotene, zinc, and copper), taken by mouth, reduced the risk of progression to advanced AMD by 25 percent, and the risk of moderate vision loss by 19 percent.

Pregnancy :: Drug Misoprostol Prevents PostPartum Hemorrhage in Resource Poor Settings

The drug misoprostol provides a safe, convenient, and inexpensive means to prevent postpartum hemorrhage, a major killer of women in developing countries. The study was conducted by researchers from the University of Missouri, India?s Jawaharlal Nehru Medical College, the National Institutes of Health, and other institutions.

DNA :: NHGRI Aims to Make DNA Sequencing Faster, More Cost Effective

Bethesda, Md. ? The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), today announced the latest round of grant awards totaling more than $13.3 million to speed the development of innovative sequencing technologies that reduce the cost of DNA sequencing and expand the use of genomics in medical research and health care.

Schizophrenia :: Solvay pharmaceuticals and Wyeth – new drug for bifeprunox to treat schizophrenia

Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) for bifeprunox, an investigational atypical antipsychotic for the treatment of schizophrenia.